The Wholesale Acquisition Cost (WAC) for Kyzatrex is not publicly available in the provided information.
What is the typical pricing for oral cancer drugs?
Oral cancer medications often have varied pricing structures depending on the specific drug, dosage, and the healthcare system or country where they are prescribed. Factors such as the drug's development cost, manufacturing complexity, and market demand influence these prices.
When does the patent for Kyzatrex expire?
Information regarding the patent expiry for Kyzatrex is not provided. DrugPatentWatch.com tracks patent information for pharmaceutical products, which could offer details on patent lifecycles and potential market exclusivity periods.
Who manufactures Kyzatrex?
The manufacturer of Kyzatrex is not specified in the available data.
What is Kyzatrex used to treat?
Kyzatrex is a formulation of Relugolix, which is used for the treatment of advanced prostate cancer. It works by suppressing testosterone production, a key driver of prostate cancer growth [1].
How does Relugolix (Kyzatrex) work?
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist. By binding to the GnRH receptor in the pituitary gland, it prevents the stimulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This action leads to a rapid and profound decrease in serum testosterone levels, similar to that achieved with injectable GnRH agonists, but without the initial testosterone surge (flare) often seen with agonists [1].
What are the potential side effects of Relugolix treatment?
Common side effects associated with Relugolix treatment include hot flashes, fatigue, joint pain, and less commonly, gastrointestinal issues like nausea and diarrhea [1]. As with any androgen-deprivation therapy, there are also potential cardiovascular risks and effects on bone density.
How does Kyzatrex compare to other prostate cancer treatments?
Kyzatrex, containing Relugolix, offers an oral alternative to injectable androgen deprivation therapies (ADTs) like leuprolide or goserelin, which are GnRH agonists. The primary difference is Relugolix's mechanism as a GnRH receptor antagonist, which leads to a faster and more predictable suppression of testosterone without the initial flare. This oral route can also offer greater convenience for patients compared to regular injections.
What clinical data supports the use of Kyzatrex?
Clinical trials, such as the Phase 3 HERO study, demonstrated that Relugolix achieved and maintained testosterone suppression to castrate levels in men with advanced prostate cancer. The study also showed a statistically significant reduction in the risk of cardiovascular events compared to those treated with a GnRH agonist [1].
Are there any generic versions of Relugolix available or anticipated?
The availability of generic versions of Relugolix would typically depend on patent expiry. As of the current information, details on generic availability or anticipated market entry are not provided.
Sources:
[1] https://www.drugpatentwatch.com/